 The Evelo-owned patent covers the use of a proprietary Bifidobacterium strain for the treatment of cancer, including use in combination with anti-PD-1 antibodies and other checkpoint inhibitors, and is relevant to the Companys ongoing Phase 12 clinical trial in oncology. The issuance of this patent reflects the strength of our platform and the capabilities of our scientists to identify microbial strains with compelling pharmacology, said Natalie Lissy, Senior Director of IP at Evelo. Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAXTM, the small intestinal axis, with systemic therapeutic effects. 